創薬市場：薬剤タイプ、技術、治療領域、エンドユーザー別-2025-2030年の世界予測

創薬市場は2023年に623億8,000万米ドルとなり、2024年には711億2,000万米ドル、CAGR14.10％で成長し、2030年には1,571億3,000万米ドルに達すると予測されています。

創薬の進化を包括的に導入

近年、創薬分野は従来の研究パラダイムを超えた進化を遂げています。この変革の原動力となっているのは、科学的イノベーション、先端技術、そして刻々と変化する規制・市場環境の融合です。多角的な洞察と最先端の手法の活用に向けた業界の取り組みは、研究室でのブレークスルーから実行可能な治療解決策への道のりを加速させようと利害関係者が努力する中で、かつてないほど重要になっています。

計算生物学、実験プロトコルの自動化、データサイエンスの統合における最近の動向は、初期段階の医薬品開発の進め方を再定義しています。組織は、高スループットスクリーニングプロセスを合理化するだけでなく、生物学的分析精度を高めるアジャイルテクノロジーへの投資をますます増やしています。このような取り組みにより、創薬ライフサイクルは、反復学習と迅速なプロトタイピングが標準となりつつある、より相互接続的で応答性の高いものとなっています。そうすることで、この部門は、臨床上の課題を克服しながら、効果的な治療法に対する需要の高まりに応えることができます。

さらに、学術界、医薬品開発業務受託機関、大手製薬企業間の連携が、この業界の協調的な基調を作り上げています。このように学際的なパートナーシップと機能横断的な研究が重視されるようになったことは、今日の創薬状況における変革的なアジェンダを強調するものであり、複雑な疾患プロファイルに対応する革新的な治療介入の基盤を築くものです。

創薬の情勢を再定義する転換期

創薬領域は、その基本的なオペレーションの枠組みを再定義するような、変革的な変化を遂げつつあります。この変化の大きな原動力となっているのは、技術の進歩の急速なペースであり、かつては煩雑であった研究開発のサイクルを、合理化されたデータ主導のプロセスに変えつつあります。新たな技術が従来の研究ワークフローに統合され続けるにつれて、この業界は、科学的厳密さと自動化および計算モデリングとのシームレスな融合を目の当たりにしています。

人工知能、強化された画像技術、ロバストなデータ解析の進歩は、リード化合物の同定を加速するだけでなく、臨床検証の精度をも高めています。このシフトは、個別化医療が世界的に重視されていることによっても補完されており、個別化医療では、患者集団の不均一性に対処する治療アプローチがより効果的になると期待されています。さらに、進化する規制の枠組みは、安全性を損なうことなく、より迅速な承認プロセスをサポートし、イノベーションと俊敏性を重視するエコシステムを育成しています。

このようなダイナミックな変化は、コラボレーションが最も重要であるという風土を育んできました。研究機関、バイオテクノロジー新興企業、既存の製薬会社は、複雑な治療課題に取り組むために、リソースと専門知識を結集しています。このようなテクノロジーとサイエンスの広範な統合は、リスク管理と最先端のツールへの投資が長期的な競争優位性を維持する上で極めて重要な、創薬の新時代の舞台を整えつつあります。

将来の研究領域を形成する主要なセグメンテーションの洞察

市場セグメンテーションを綿密に調べると、創薬業界には何層もの専門分野があることがわかる。業界は薬剤の種類に基づいてセグメント化されており、詳細な調査では生物学的製剤と低分子薬剤が区別されています。この区別は、開発パイプライン、規制の経路、市場導入戦略に大きな影響を与えます。

技術面では、バイオ分析機器、バイオチップ、バイオインフォマティクスなど、様々な洗練されたツールが導入され、現代の研究のバックボーンとなっています。コンビナトリアルケミストリー、ハイスループットスクリーニング、ナノテクノロジーなどの先端技術も最前線にあり、薬理ゲノミクスは個別化医療や標的療法への道を開いています。これらの技術分野は、医薬品開発を迅速化し、治療標的の精度を確保することで大きな価値をもたらしています。

治療分野に基づくさらなる細分化は、創薬努力の的を絞った応用を強調しています。心血管疾患、消化器系疾患、感染症・免疫系疾患、神経学、腫瘍学などの重要な重点領域は、独自の研究アプローチを必要とする多様な臨床環境を示しています。最後に、学術界、研究機関、開発業務受託機関、大手製薬会社など、エンドユーザーに基づくセグメンテーションは、市場力学を重層的に示しています。このようにセグメンテーションの洞察を統合することで、利害関係者は特定の市場ニーズや臨床課題に戦略を合わせることができ、研究収益と臨床の成功を最大化することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬・バイオ医薬品業界における研究開発費の増加
    • 前臨床研究中に生成される大量のデータを管理する必要性の高まり
    • 創薬プラットフォームの開発に対する政府の好意的な支援
  • 抑制要因
    • 創薬と開発のための多額の資本の必要性
  • 機会
    • 企業間の新たなコラボレーションにより、創薬の能力が拡大
    • 創薬における技術の進歩と革新
    • AIクラウドを使用して創薬で合理化された自動化されたアプローチを作成します
  • 課題
    • 創薬における動物の使用に関する厳格な規範
• 市場セグメンテーション分析
  • 医薬品の種類：ブランド薬とジェネリック薬による低分子医薬品の需要増加
  • 技術：初期段階におけるバイオ分析機器とハイスループットスクリーニングの利用拡大
  • 治療領域：腫瘍治療薬の開発における創薬の必要性の高まり
  • エンドユーザー：製薬会社やバイオテクノロジー会社で新薬や改良薬の開発に創薬の使用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 創薬市場薬剤の種類別

• 生物学的製剤
• 低分子医薬品

第7章 創薬市場：技術別

• バイオ分析機器
• バイオチップ
• バイオインフォマティクス
• コンビナトリアルケミストリー
• ハイスループットスクリーニング
• ナノテクノロジー
• 薬理ゲノミクス

第8章 創薬市場治療領域別

• 心血管疾患
• 消化器系疾患
• 感染症および免疫系疾患
• 神経学
• 腫瘍学

第9章 創薬市場：エンドユーザー別

• 学術機関および調査機関
• 契約調査機関
• 製薬会社

第10章 南北アメリカの創薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の創薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの創薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies, Inc.
• Alacrita Holdings Limited
• Alkem Laboratories Ltd
• Amgen Inc.
• Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
• Astrazeneca PLC
• Atomwise, Inc.
• BenevolentAI
• Bio-Rad Laboratories, Inc.
• BioSymetrics Inc.
• Charles River Laboratories International, Inc.
• Chembridge Corporation
• Cloud Pharmaceuticals, Inc.
• Dalriada Drug Discovery
• Deciphera Pharmaceuticals, Inc.
• Eli Lilly and Company
• Evotec SE
• Exscientia PLC
• F. Hoffmann-La Roche Ltd.
• GENFIT SA
• Incyte Corporation
• International Business Machines Corporation
• Intra-Cellular Therapies Inc.
• Kvantify
• Lantern Pharma Inc.
• Merck KGaA
• Microsoft Corporation
• NVIDIA Corporation
• PerkinElmer, Inc.
• Pharmacelera SL
• Piramal Group
• Recursion Pharmaceuticals, Inc.
• Sanofi S.A
• Schrodinger, Inc.
• Shimadzu Corporation
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. DRUG DISCOVERY MARKET MULTI-CURRENCY
• FIGURE 2. DRUG DISCOVERY MARKET MULTI-LANGUAGE
• FIGURE 3. DRUG DISCOVERY MARKET RESEARCH PROCESS
• FIGURE 4. DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DRUG DISCOVERY MARKET DYNAMICS
• TABLE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. CANADA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 42. CANADA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 43. CANADA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 44. CANADA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 64. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 66. CHINA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. INDIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. INDIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 70. INDIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. ITALY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 137. ITALY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 138. ITALY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 139. ITALY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. POLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 153. POLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 154. POLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 155. POLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 156. QATAR DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 157. QATAR DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 158. QATAR DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 159. QATAR DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 196. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 197. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

The Drug Discovery Market was valued at USD 62.38 billion in 2023 and is projected to grow to USD 71.12 billion in 2024, with a CAGR of 14.10%, reaching USD 157.13 billion by 2030.

A Comprehensive Introduction to the Evolution of Drug Discovery

In recent years, the field of drug discovery has experienced an evolution that transcends traditional research paradigms. This transformation is driven by the convergence of scientific innovation, advanced technology, and an ever-changing regulatory and market environment. The industry's commitment to leveraging multidimensional insights and cutting-edge methodologies is now more critical than ever, as stakeholders strive to accelerate the journey from laboratory breakthroughs to viable therapeutic solutions.

Recent advancements in computational biology, automation of experimental protocols, and integration of data science have redefined how early-stage drug development is conducted. Organizations are increasingly investing in agile technologies that not only streamline high throughput screening processes but also enhance bioanalytical accuracy. These efforts have led to a more interconnected and responsive drug discovery lifecycle, where iterative learning and rapid prototyping are becoming the norm. In doing so, the sector positions itself to meet the growing demand for effective therapies while overcoming clinical challenges.

Furthermore, collaboration across academia, contract research organizations, and large pharmaceutical companies has set a collaborative tone for the industry. This heightened focus on interdisciplinary partnerships and cross-functional research underscores the transformative agenda of today's drug discovery landscape, laying the foundation for innovative therapeutic interventions that address complex disease profiles.

Transformative Shifts Redefining the Drug Discovery Landscape

The drug discovery arena is undergoing transformative shifts that have redefined its fundamental operational framework. A significant driver of this change is the rapid pace of technological advancement, which is turning once cumbersome cycles of research and development into streamlined, data-driven processes. As emerging technologies continue to integrate into traditional research workflows, the industry witnesses a seamless blend of scientific rigor with automation and computational modeling.

Advancements in artificial intelligence, enhanced imaging techniques, and robust data analytics are not only accelerating the identification of lead compounds but also enhancing the precision of clinical validation. This shift is further complemented by a global emphasis on personalized medicine, where tailored therapeutic approaches promise to address the heterogeneity of patient populations more effectively. Moreover, evolving regulatory frameworks are supporting faster approval processes without compromising safety, thereby cultivating an ecosystem that prizes innovation and agility.

These dynamic changes have fostered a climate where collaboration is paramount. Research institutions, biotech startups, and established pharmaceutical companies are pooling resources and expertise to tackle complex therapeutic challenges. Such broad-based integration of technology and science is setting the stage for a new era in drug discovery, where risk management and investment in state-of-the-art tools are pivotal to sustaining long-term competitive advantage.

Key Segmentation Insights Shaping the Future Research Arena

A meticulous examination of market segmentation reveals multiple layers of specialization within drug discovery. The industry is segmented based on drug type, where an in-depth study distinguishes between biologic drugs and small molecule drugs. This differentiation has profound implications on developmental pipelines, regulatory pathways, and market adoption strategies.

From a technology perspective, the landscape has embraced a range of sophisticated tools, including bioanalytical instruments, biochips, and bioinformatics, which form the backbone of modern research. Advanced techniques such as combinatorial chemistry, high throughput screening, and nanotechnology are also at the forefront, while pharmacogenomics is paving the way towards personalized care and targeted therapies. These technological segments contribute significant value by expediting drug development and ensuring precision in therapeutic targeting.

Further segmentation based on therapeutic areas underscores the targeted application of drug discovery efforts. Critical focus areas such as cardiovascular disease, digestive system diseases, infectious and immune system diseases, neurology, and oncology illustrate the diverse clinical settings that demand distinct research approaches. Finally, segmentation based on end users, which spans the academic community, research institutions, and contract research organizations, as well as large pharmaceutical companies, presents a layered view of market dynamics. This integration of segmentation insights empowers stakeholders to align strategies with specific market needs and clinical challenges, thereby maximizing research returns and clinical success.

Based on Drug Type, market is studied across Biologic Drugs and Small Molecule Drugs.

Based on Technology, market is studied across Bioanalytical Instruments, Biochips, Bioinformatics, Combinatorial Chemistry, High Throughput Screening, Nanotechnology, and Pharmacogenomics.

Based on Therapeutic Area, market is studied across Cardiovascular Disease, Digestive System Diseases, Infectious & Immune system Diseases, Neurology, and Oncology.

Based on End User, market is studied across Academics & Research Institutes, Contract Research Organizations, and Pharmaceutical Companies.

Regional Insights: A Global Perspective on Drug Discovery Innovation

The regional dynamics of drug discovery further enrich the analysis of this rapidly transforming industry. The Americas, with its robust infrastructural support for research and development, continues to lead in innovation. Intricate networks of academic institutions, biotech startups, and major pharmaceutical hubs create an environment ripe for transformative research and seamless commercialization of new therapies.

In Europe, Middle East, and Africa, a unique blend of regulatory precision and market demand fosters an ecosystem where breakthrough innovations reliably move from bench to bedside. This region's commitment to integrating advanced technological infrastructures with conventional research methodologies is notable, as it attracts significant global investment and collaborative efforts.

Across the Asia-Pacific region, rapid economic growth coupled with a surge in population-based studies and government-supported healthcare initiatives has accelerated advancements in drug discovery. In this diverse market, strategic partnerships and localized research initiatives play pivotal roles, driving faster adoption of cutting-edge technologies and broadening the scope of therapeutic research. These regional insights highlight a global breadth of innovation that reinforces the necessity for decentralized yet coordinated approaches to drug discovery.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Georgia, Illinois, Indiana, Michigan, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Company Insights in the Evolving Drug Discovery Fabric

Analyzing the contributions of key players in the market reveals the competitive intensity within the drug discovery space. Prominent companies such as Abbott Laboratories, Agilent Technologies, Inc., and Alacrita Holdings Limited are continually pushing the envelope by developing and integrating groundbreaking technologies. These organizations, alongside leaders like Alkem Laboratories Ltd and Amgen Inc., are setting benchmarks in drug development practices.

The influence of firms such as Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd., Astrazeneca PLC, and Atomwise, Inc. is evident in their relentless pursuit of innovative therapy development. Investments by BenevolentAI and Bio-Rad Laboratories, Inc. further highlight the drive towards harnessing artificial intelligence and data analytics to streamline discovery processes. Moreover, contributions from organizations like BioSymetrics Inc. and Charles River Laboratories International, Inc. have played a crucial role in refining experimental protocols and enhancing regulatory compliance.

Other notable companies such as Chembridge Corporation, Cloud Pharmaceuticals, Inc., Dalriada Drug Discovery, and Deciphera Pharmaceuticals, Inc. are strategically positioned to leverage emerging computational tools and novel research methodologies. The strategic alliances and technology integrations championed by Eli Lilly and Company, Evotec SE, Exscientia PLC, and F. Hoffmann-La Roche Ltd. underscore the importance of collaborative innovation. With further contributions from GENFIT SA, Incyte Corporation, International Business Machines Corporation, Intra-Cellular Therapies Inc., Kvantify, Lantern Pharma Inc., Merck KGaA, Microsoft Corporation, NVIDIA Corporation, PerkinElmer, Inc., Pharmacelera SL, and Piramal Group, the market is characterized by a rich interplay of scientific expertise and commercial acumen. Continuing this momentum, Recursion Pharmaceuticals, Inc., Sanofi S.A, Schrodinger, Inc., Shimadzu Corporation, and Thermo Fisher Scientific Inc. exemplify the dynamic and integrated nature of modern drug discovery endeavors.

The report delves into recent significant developments in the Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Alacrita Holdings Limited, Alkem Laboratories Ltd, Amgen Inc., Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd., Astrazeneca PLC, Atomwise, Inc., BenevolentAI, Bio-Rad Laboratories, Inc., BioSymetrics Inc., Charles River Laboratories International, Inc., Chembridge Corporation, Cloud Pharmaceuticals, Inc., Dalriada Drug Discovery, Deciphera Pharmaceuticals, Inc., Eli Lilly and Company, Evotec SE, Exscientia PLC, F. Hoffmann-La Roche Ltd., GENFIT SA, Incyte Corporation, International Business Machines Corporation, Intra-Cellular Therapies Inc., Kvantify, Lantern Pharma Inc., Merck KGaA, Microsoft Corporation, NVIDIA Corporation, PerkinElmer, Inc., Pharmacelera SL, Piramal Group, Recursion Pharmaceuticals, Inc., Sanofi S.A, Schrodinger, Inc., Shimadzu Corporation, and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders Navigating Change

Industry leaders should adopt a dynamic approach to address current challenges and sustain future growth. Embracing cross-disciplinary research efforts and investing in next-generation technologies is imperative for maintaining competitive advantage. Decision-makers are encouraged to prioritize initiatives that facilitate collaboration between academic research teams, contract research organizations, and established pharmaceutical companies, thereby creating a unified framework for agile innovation.

For organizations aiming to reduce time-to-market, integrating high throughput screening, advanced bioinformatics, and nanotechnology can result in more efficient identification of lead compounds. Investing in sophisticated bioanalytical instruments and leveraging combinatorial chemistry will further enhance the fidelity and speed of discovery processes. Such strategic investments not only optimize operational workflows but also foster a culture of innovation and continuous improvement.

It is advisable for stakeholders to closely monitor emerging regulatory trends and seek strategic partnerships that align with evolving market demands. Building robust digital infrastructures capable of managing large datasets and predictive analytics is a crucial step in driving success. Furthermore, tailoring therapeutic strategies to target specific clinical areas, such as oncology and neurology, will likely yield higher returns on investment. Ultimately, a cohesive strategy that blends technological adoption with market-specific insights will empower industry leaders to effectively navigate the rapidly evolving landscape.

Conclusion: Embracing Change for a Future-Ready Drug Discovery Ecosystem

The shifting paradigms within drug discovery underscore a transformative era marked by technological sophistication, strategic segmentation, and expansive global collaborations. In summary, the industry is reaping the benefits of advanced computational methods, dynamic regional investments, and the collective expertise of pioneering companies. These factors converge to create a fertile ground for innovation that is both economically and scientifically sustainable.

A robust drug discovery framework today is defined by its openness to disruptive technologies and cross-sectoral partnerships. As the market continues to evolve, stakeholders across the spectrum must continually reassess investment strategies while embracing integrated workflows that streamline the research and development process. The synthesis of advanced technological integrations with strategic market insights ensures that the drug discovery ecosystem is poised to deliver novel therapeutic solutions that address unmet clinical needs.

In essence, the future of drug discovery hinges on our ability to harness innovation, collaborate across traditional silos, and implement forward-thinking solutions that respond to the challenges of an increasingly complex global landscape. The journey ahead is one of both opportunity and responsibility, requiring all players to be agile, innovative, and collaborative in their pursuit of scientific excellence.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising R&D expenditure in the pharmaceutical & biopharmaceutical industry
    • 5.1.1.2. Increasing need to manage large data generated during preclinical studies
    • 5.1.1.3. Favorable government support for the development of drug discovery platforms
  • 5.1.2. Restraints
    • 5.1.2.1. Requirement of extensive capital for drug discovery and development
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging collaborations among companies to expand their drug discovery capabilities
    • 5.1.3.2. Technological advancements and innovations in drug discovery
    • 5.1.3.3. Use of AI cloud to create a streamlined and automated approach in drug discovery
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent norms for animal usage in drug discovery
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Growing need for small molecule drugs with branded and generic products
  • 5.2.2. Technology: Growing utilization of bioanalytical instruments and high throughput screening for initial drug discovery phases
  • 5.2.3. Therapeutic Area: Increasing need of drug discovery for the development of oncology drugs
  • 5.2.4. End User: Growing drug discovery use across pharmaceutical and biotechnology companies for developing new and improved drugs
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Drug Discovery Market, by Drug Type

• 6.1. Introduction
• 6.2. Biologic Drugs
• 6.3. Small Molecule Drugs

7. Drug Discovery Market, by Technology

• 7.1. Introduction
• 7.2. Bioanalytical Instruments
• 7.3. Biochips
• 7.4. Bioinformatics
• 7.5. Combinatorial Chemistry
• 7.6. High Throughput Screening
• 7.7. Nanotechnology
• 7.8. Pharmacogenomics

8. Drug Discovery Market, by Therapeutic Area

• 8.1. Introduction
• 8.2. Cardiovascular Disease
• 8.3. Digestive System Diseases
• 8.4. Infectious & Immune system Diseases
• 8.5. Neurology
• 8.6. Oncology

9. Drug Discovery Market, by End User

• 9.1. Introduction
• 9.2. Academics & Research Institutes
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical Companies

10. Americas Drug Discovery Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Drug Discovery Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Drug Discovery Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Exscientia PLC partners with AWS to harness AI and cloud technology for accelerating drug discovery and reducing costs
  • 13.3.2. Enzene Biosciences launches new drug discovery division offering integrated services
  • 13.3.3. Emory University's Center for New Medicines accelerates drug discovery with advanced technology for improved patient outcomes and collaborative research.
  • 13.3.4. Oregon Therapeutics partners with Lantern Pharma to advance XCE853 development using RADR AI platform, targeting drug-resistant cancers
  • 13.3.5. Xaira Therapeutics launches with over USD 1 billion funding to revolutionize AI-driven drug discovery with innovative machine learning models
  • 13.3.6. bioXcelerate launches PleioGraph AI tool to revolutionize drug discovery, cutting costs and accelerating treatments by 100x
  • 13.3.7. UC Berkeley's Molecular Therapeutics Initiative (MTI) aims to accelerate breakthrough treatments for neurological, metabolic diseases, and cancer through interdisciplinary collaboration
  • 13.3.8. Danish quantum computing firm Kvantify unveils Kvantify Koffee to revolutionize drug discovery with expedited screening, cost reduction, and future-proof technology integration
  • 13.3.9. Washington University and Deerfield Management partner to launch VeritaScience, committing USD 130 million to advance drug discovery and development
  • 13.3.10. Arena BioWorks opens in Kendall Square with USD 500 million to accelerate drug discovery and market innovative medicines.
  • 13.3.11. Evommune and Accutar Biotechnology announce AI drug discovery collaboration
  • 13.3.12. IGC Pharma signs agreement to adopt AI solutions into drug discovery
  • 13.3.13. University of Tsukuba and Astellas Pharma Inc. confirm a strategic partnership
  • 13.3.14. Sosei and PharmEnable collaborate on another neurological drug
  • 13.3.15. Novo Nordisk and Evotec launch translational drug discovery accelerator
  • 13.3.16. Genesis raises USD 200 million for AI drug discovery research
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. NVIDIA Corporation
  • 13.4.2. F. Hoffmann-La Roche Ltd.
  • 13.4.3. Exscientia PLC
  • 13.4.4. Alkem Laboratories Ltd

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. Alacrita Holdings Limited
• 4. Alkem Laboratories Ltd
• 5. Amgen Inc.
• 6. Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
• 7. Astrazeneca PLC
• 8. Atomwise, Inc.
• 9. BenevolentAI
• 10. Bio-Rad Laboratories, Inc.
• 11. BioSymetrics Inc.
• 12. Charles River Laboratories International, Inc.
• 13. Chembridge Corporation
• 14. Cloud Pharmaceuticals, Inc.
• 15. Dalriada Drug Discovery
• 16. Deciphera Pharmaceuticals, Inc.
• 17. Eli Lilly and Company
• 18. Evotec SE
• 19. Exscientia PLC
• 20. F. Hoffmann-La Roche Ltd.
• 21. GENFIT SA
• 22. Incyte Corporation
• 23. International Business Machines Corporation
• 24. Intra-Cellular Therapies Inc.
• 25. Kvantify
• 26. Lantern Pharma Inc.
• 27. Merck KGaA
• 28. Microsoft Corporation
• 29. NVIDIA Corporation
• 30. PerkinElmer, Inc.
• 31. Pharmacelera SL
• 32. Piramal Group
• 33. Recursion Pharmaceuticals, Inc.
• 34. Sanofi S.A
• 35. Schrodinger, Inc.
• 36. Shimadzu Corporation
• 37. Thermo Fisher Scientific Inc.